18 F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging

Abstract

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with 68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world.However, recent years have witnessed the start of a shift from 68 Ga-to 18 F-labeled PSMA-targeted compounds.The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic.First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite 68 Ge/ 68 Ga generator.Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production.Moreover, 18 F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions.In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy.Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron.In light of these advantageous characteristics, 18 F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available.We have aimed to provide a concise overview of emerging 18 F-labeled PSMA-targeted radiotracers undergoing active clinical development.Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available 18 F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.

References 109

1. 1.

   Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016;19:395-7.

   Not in our library10.1038/pcan.2016.30

2. 2.

   Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.

   Not in our library10.3322/caac.21442

3. 3.

   Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46:3040-52.

   Not in our library10.1016/j.ejca.2010.09.013

4. 4.

   Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70:926-37.

   Not in our library10.1016/j.eururo.2016.06.021

5. 5.

   PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol. 2016;18:411-9.

   Not in our library10.1007/s11307-016-0957-6

6. 6.

   (68)Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019;46:31-9.

   Not in our library10.1007/s00259-018-4189-7

7. 7.

   German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017;58:85-90.

   Not in our library10.2967/jnumed.116.183194

8. 8.

   Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125-35.

   Not in our library10.1056/nejmoa1607427

9. 9.

   The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics. 2018;8:6088-100.

   Not in our library10.7150/thno.30357

10. 10.
    225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study · 2018

    Corrected
11. 11.

    Theranostic Concepts: More Than Just a Fashion Trend-Introduction and Overview. J Nucl Med. 2017;58:1S-2S.

    Not in our library10.2967/jnumed.117.199570

12. 12.

    [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825-33.

    Not in our library10.1016/s1470-2045(18)30198-0

13. 13.

    PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 2015;5:1388-401.

    Not in our library10.7150/thno.13348

14. 14.

    Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015;17:565-74.

    Not in our library10.1007/s11307-015-0850-8

15. 15.

    Moving into the next era of PET myocardial perfusion imaging: introduction of novel (18)F-labeled tracers. 2018.

    Not in our library10.1007/s10554-018-1469-z

16. 16.

    Recent paradigm shifts in molecular cardiac imaging-Establishing precision cardiology through novel (18)F-labeled PET radiotracers. 2019.

    Not in our library10.1016/j.tcm.2019.02.007

17. 17.

    Practical Aspects of 18F-FDG PET When Receiving 18F-FDG from a Distant Supplier. J Nucl Med Technol. 2009;37:164-9.

    Not in our library10.2967/jnmt.109.062950

18. 18.
    Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer · 2015

    No notice
19. 19.

    PSA-Stratified Performance of (18)F- and (68)Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2017;58:947-52.

    Not in our library10.2967/jnumed.116.185538

20. 20.

    Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution. Cancer Imaging. 2019;19:23.

    Not in our library10.1186/s40644-019-0211-y

21. 21.

    2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645-53.

    Not in our library10.1158/1078-0432.ccr-11-1357

22. 22.

    18F-Labeled Peptides: The Future Is Bright. Molecules. 2014;19:20536-56.

    Not in our library10.3390/molecules191220536

23. 23.

    Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2015;26:1-18.

    Not in our library10.1021/bc500475e

24. 24.

    Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-91.

    Not in our library10.2967/jnumed.112.104661

25. 25.

    (1)(8)F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med. 2015;56:1003-10.

    Not in our library10.2967/jnumed.115.154336

26. 26.

    Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med. 2016;57:46-53.

    Not in our library10.2967/jnumed.115.163782

27. 27.

    18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology. Clin Nucl Med. 2017;42:735-40.

    Not in our library10.1097/rlu.0000000000001804

28. 28.

    Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging. 2018;45:4-11.

    Not in our library10.1007/s00259-017-3818-x

29. 29.

    Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:89-101.

    Not in our library10.1007/s00259-013-2527-3

30. 30.

    BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study). Mol Imaging Biol. 2015;17:424-33.

    Not in our library10.1007/s11307-014-0800-x

31. 31.
    F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients · 2016

    No notice
32. 32.

    First-in-Human Phase I study of CTT1057, a Novel (18)F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. 2018.

    Not in our library10.2967/jnumed.118.220715

33. 33.

    Initial evaluation of PET/CT with (18) F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients. Cancer Sci. 2019;110:742-50.

    Not in our library10.1111/cas.13911

34. 34.

    Discovery of (18)F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions. 2018.

    Not in our library10.2967/jnumed.118.218495

35. 35.

    In vitro and in vivo characterization of a 18F-AlF-labeled PSMA ligand for imaging of PSMA-expressing xenografts. J Nucl Med. 2019;60:1017-22.

    Not in our library10.2967/jnumed.118.218941

36. 36.

    Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. J Nucl Med. 2016;57:90S-6S.

    Not in our library10.2967/jnumed.115.170175

37. 37.

    Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55-62.

    Not in our library10.1016/j.apradiso.2012.06.034

38. 38.

    Physical performance comparison of Ga-68 and F-18 in small animal PET system. J Nucl Med. 2010;51:1423.

    Not in our library

39. 39.

    Gallium-68 EDTA PET/CT for Renal Imaging. Semin Nucl Med. 2016;46:448-61.

    Not in our library10.1053/j.semnuclmed.2016.04.002

40. 40.

    Editorial commentary: Potential for personalized imaging with new radiotracers and cardiac PET. 2019.

    Not in our library10.1016/j.tcm.2019.04.010

41. 41.

    The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. AJR Am J Roentgenol. 2003;181:359-65.

    Not in our library10.2214/ajr.181.2.1810359

42. 42.

    Health and Health Care of Medicare Beneficiaries in 2030. Forum Health Econ Policy. 2015;18:75-96.

    Not in our library10.1515/fhep-2015-0037

43. 43.

    Combined Early and Late [(68)Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. 2018.

    Not in our library10.1007/s11307-018-1263-2

44. 44.

    Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:960-8.

    Not in our library10.1007/s00259-017-3669-5

45. 45.

    68Ga-PSMA PET/MRI: Determining ideal acquisition times to reduce noise and increase image quality. J Nucl Med. 2018;59:1444.

    Not in our library10.1186/s40658-020-00322-x

46. 46.

    PET/CT imaging in cancer: current applications and future directions. Cancer. 2014;120:3433-45.

    Not in our library10.1002/cncr.28860

47. 47.

    Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. 2019.

    Not in our library10.1001/jamaoncol.2019.0096

48. 48.

    Cost / Benefit Comparison for a 45 MeV and 70 MeV Cyclotrons, Conducted by Juptier TM for the U.S. Department of Energy. May, 26, 2005.

    Not in our library

49. 49.

    Design, construction and testing of a low-cost automated (68)Gallium-labeling synthesis unit for clinical use. Am J Nucl Med Mol Imaging. 2016;6:176-84.

    Not in our library

50. 50.

    PSMA-Based Detection of Prostate Cancer Bone Lesions With (1)(8)F-DCFPyL PET/CT: A Sensitive Alternative to ((9)(9)m)Tc-MDP Bone Scan and Na(1)(8)F PET/CT? Clin Genitourin Cancer. 2016;14:e115-8.

    Not in our library10.1016/j.clgc.2015.09.011

51. 51.

    Intraindividual Comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med. 2018;59:1076-80.

    Not in our library10.2967/jnumed.117.204669

52. 52.

    (18)F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. J Nucl Med. 2017;58:1797-804.

    Not in our library10.2967/jnumed.117.192658

53. 53.

    A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. 2019.

    Not in our library10.2967/jnumed.119.226381

54. 54.

    Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117-36.

    Not in our library10.1007/s00259-017-3780-7

55. 55.

    Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Semin Nucl Med. 2019;49:255-70.

    Not in our library10.1053/j.semnuclmed.2019.02.006

56. 56.

    Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0. J Nucl Med. 2018;59:479-85.

    Not in our library10.2967/jnumed.117.195255

57. 57.

    Novel Structured Reporting Systems for Theranostic Radiotracers. J Nucl Med. 2019;60:577-84.

    Not in our library10.2967/jnumed.118.223537

58. 58.

    Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on (18)F-DCFPyL PET/CT Imaging. J Nucl Med. 2018;59:1857-64.

    Not in our library10.2967/jnumed.118.217588

59. 59.

    Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [(18)F]DCFPyL PET/CT. 2018.

    Not in our library10.1007/s11307-018-1271-2

60. 60.

    Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann Nucl Med. 2015;29:877-82.

    Not in our library10.1007/s12149-015-1017-z

61. 61.

    18F-DCFPyL PET/CT in Oncocytoma. Clin Nucl Med. 2018;43:921-4.

    Not in our library10.1097/rlu.0000000000002301

62. 62.

    Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas. Clin Nucl Med. 2018;43:e419-e21.

    Not in our library10.1097/rlu.0000000000002280

63. 63.

    Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas. Clin Nucl Med. 2017;42:e433-e5.

    Not in our library10.1097/rlu.0000000000001769

64. 64.

    Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive? J Nucl Med. 2017;58:97S-103S.

    Not in our library10.2967/jnumed.116.186841

65. 65.

    Combined model-based and patient-specific dosimetry for (18)F-DCFPyL, a PSMA-targeted PET agent. Eur J Nucl Med Mol Imaging. 2018;45:989-98.

    Not in our library10.1007/s00259-018-3939-x

66. 66.

    Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY). 2018.

    Not in our library

67. 67.

    18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clin Genitourin Cancer. 2017;15:e497-e9.

    Not in our library10.1016/j.clgc.2016.12.029

68. 68.

    Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2055-61.

    Not in our library10.1007/s00259-018-4089-x

69. 69.
    Detection Efficacy of 18 F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy · 2018

    No notice
70. 70.

    Advantage of (18)F-PSMA-1007 over (68)Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. Eur J Nucl Med Mol Imaging. 2018;45:1076-7.

    Not in our library10.1007/s00259-018-3952-0

71. 71.

    (18)F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45:1329-34.

    Not in our library10.1007/s00259-018-3989-0

72. 72.

    JOIN THE [18F]PSMA-1007 GLOBAL ACADEMIC INITIATIVE. 2019.

    Not in our library

73. 73.

    Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. 2019.

    Not in our library10.2967/jnumed.119.229187

74. 74.

    A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015;42:780-7.

    Not in our library10.1016/j.nucmedbio.2015.06.003

75. 75.

    (177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 2017;7:1928-39.

    Not in our library10.7150/thno.18719

76. 76.
    Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer · 2013

    No notice
77. 77.

    Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. J Nucl Med. 2016;57:1978-84.

    Not in our library10.2967/jnumed.116.175810

78. 78.

    Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia. Ann Nucl Med. 2017;31:696-702.

    Not in our library10.1007/s12149-017-1201-4

79. 79.

    (68)Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. J Nucl Med. 2018;59:1406-11.

    Not in our library10.2967/jnumed.117.204677

80. 80.

    Biodistribution and radiation dosimetry of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. J Nucl Med. 2018;59:88.

    Not in our library

81. 81.

    Performance of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. J Nucl Med. 2018;59:452.

    Not in our library

82. 82.

    Synthesis and preclinical evaluation of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging. 2016;43:2122-30.

    Not in our library10.1007/s00259-016-3437-y

83. 83.

    Automated radiosynthesis of Al[(18)F]PSMA-11 for large scale routine use. Appl Radiat Isot. 2018;135:19-27.

    Not in our library10.1016/j.apradiso.2018.01.006

84. 84.

    Validation of a [Al(18)F]PSMA-11 preparation for clinical applications. Appl Radiat Isot. 2017;130:102-8.

    Not in our library10.1016/j.apradiso.2017.09.003

85. 85.

    Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform. EJNMMI Radiopharm Chem. 2018;3:4.

    Not in our library10.1186/s41181-018-0039-y

86. 86.

    Radiation dosimetry and biodistribution of (18)F-PSMA-11 for PET imaging of prostate cancer. 2019.

    Not in our library10.2967/jnumed.118.225250

87. 87.

    PET/CT evaluation of prostate cancer patients with Al18F-PSMA-HBED-CC: a head-to-head comparison with 68Ga-PSMA-HBED-CC. 2018;59.

    Not in our library

88. 88.

    Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9-32.

    Not in our library10.20892/j.issn.2095-3941.2016.0084

89. 89.
    Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007 · 2018

    Not checked
90. 90.

    Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. 2019.

    Not in our library10.1007/s11307-019-01375-w

91. 91.

    Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE. 2019.

    Not in our library10.2967/jnumed.119.228072

92. 92.

    Molecular Imaging of Prostate Cancer: Choosing the Right Agent. J Nucl Med. 2018;59:787-8.

    Not in our library10.2967/jnumed.117.206318

93. 93.

    Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging. Clin Nucl Med. 2017;42:e286-e93.

    Not in our library10.1097/rlu.0000000000001589

94. 94.

    Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus. J Nucl Med. 2019;60:7-8.

    Not in our library10.2967/jnumed.118.219386

95. 95.

    177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016;57:1006-13.

    Not in our library10.2967/jnumed.115.168443

96. 96.

    Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019;9:2595-605.

    Not in our library10.7150/thno.32376

97. 97.

    (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Theranostics. 2016;6:1619-28.

    Not in our library10.7150/thno.15344

98. 98.

    Comparison Between (64)Cu-PSMA-617 PET/CT and (18)F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clin Genitourin Cancer. 2018;16:385-91.

    Not in our library10.1016/j.clgc.2018.05.014

99. 99.

    89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-300.

    Not in our library10.2967/jnumed.110.076174

100. 100.

     A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014;191:1439-45.

     Not in our library10.1016/j.juro.2013.10.041

101. 101.

     A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin Cancer Res. 2015;21:5277-85.

     Not in our library10.1158/1078-0432.ccr-15-0552

102. 102.

     Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics. 2017;7:4359-69.

     Not in our library10.7150/thno.20586

103. 103.

     Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. Clin Nucl Med. 2016;41:e397-402.

     Not in our library10.1097/rlu.0000000000001273

104. 104.

     Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530-4.

     Not in our library10.1016/j.eururo.2015.04.034

105. 105.

     Prospective Evaluation of PSMA-Targeted (18)F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. 2019.

     Not in our library10.2967/jnumed.119.226514

106. 106.

     Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. 2019.

     Not in our library10.1016/j.eururo.2019.01.049

107. 107.

     Detection Rate of (18)F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. 2019;11.

     Not in our library10.3390/cancers11050710

108. 108.

     Impact of (68)Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018;74:179-90.

     Not in our library10.1016/j.eururo.2018.03.030

109. 109.

     A novel 18F-labeled PSMA ligand for PET/CT imaging of prostate cancer patients: First -in- man observational study and clinical experience with 18F-JK-PSMA-7 during the first year of application. 2019.

     Not in our library10.2967/jnumed.119.229542

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.